MAB Discovery has added Sanofi to its list of partners through a monoclonal antibody research and license agreement announced today. As part of the agreement, MAB Discovery will develop therapeutic antibodies for selected targets from Sanofi. In return, Sanofi will receive antibodies with the aim of identifying active substances for a number of difficult-to-treat diseases.
Two similar deals were signed in 2014. In May, Synthon Biopharmaceuticals inked a deal with MAB Discovery to support development of antibody-drug conjugates (ADCs) and alternative antibody-based therapeutics. And in March, MAB Discovery cut a deal with Genmab to produce antibodies for multiple Genmab targets to help Genmab develop its therapeutic antibody products.
